Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) issued its earnings results on Monday. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.04), Fidelity Earnings reports.
Brainstorm Cell Therapeutics Stock Performance
Brainstorm Cell Therapeutics stock opened at $3.45 on Tuesday. The stock has a market cap of $125.89 million, a P/E ratio of -5.39 and a beta of 0.05. Brainstorm Cell Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $4.70. The firm’s fifty day moving average price is $2.80 and its 200-day moving average price is $3.01.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on shares of Brainstorm Cell Therapeutics in a report on Wednesday, August 10th. They issued a “hold” rating on the stock.
Institutional Inflows and Outflows
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
- Get a free copy of the StockNews.com research report on Brainstorm Cell Therapeutics (BCLI)
- 3 Blowout Earnings Reports That Could Mark Turning Points
- 3 Stocks Set to Lead the Nasdaq Bull Market
- Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
- Skyworks Solutions Is Worth A Look At These Prices
- MarketBeat Podcast: ESG – Profitably Invest Your Values
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.